Eli Lilly and Company $LLY Shares Purchased by Voleon Capital Management LP

Key Points

• Voleon Capital Management LP increased its stake in Eli Lilly by 32.9% in the first quarter, acquiring an additional 2,415 shares, bringing its total holdings to 9,753 shares valued at approximately $8.05 million.
• Eli Lilly reported earnings per share (EPS) of $6.31 for the last quarter, exceeding analyst estimates by $0.72, and its revenue grew by 37.6% year-over-year to $15.56 billion.
$1.50 per share, resulting in an annualized dividend yield of 0.8%.

Voleon Capital Management LP raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 32.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,753 shares of the company's stock after acquiring an additional 2,415 shares during the quarter. Voleon Capital Management LP's holdings in Eli Lilly and Company were worth $8,055,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. WestEnd Advisors LLC increased its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth $27,000. Citizens National Bank Trust Department raised its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after buying an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. UBS Group reduced their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Morgan Stanley restated an "overweight" rating and set a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, Cantor Fitzgerald dropped their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $11.35 during mid-day trading on Tuesday, reaching $749.99. 2,983,536 shares of the stock traded hands, compared to its average volume of 4,436,129. The stock has a market capitalization of $709.84 billion, a PE ratio of 49.02, a PEG ratio of 1.03 and a beta of 0.47. The business has a 50-day moving average of $743.02 and a 200 day moving average of $779.63. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $942.35. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.